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In our earlier work [lOI on aminor~bosyl-bound prodrugs of adriamy~in (ADR) using 
poly(a-L-glutamic acid) (PGA) grafted in high yield (90-l 00 mol.%) with various peptide 
spacers as a plasma-soluble macromolecular carrier we observed rather low cytotoxie activi- 
ties in L1210 leukemia and B16 melanoma in vitro assays. These results may be tentatively 
explained by a decreased susceptibility of the spacer-bound adriamycin moiety to hydrolysis 
by lysosomal enzymes due to the high spacer load. This hypothesis was tested by the study 
of two conjugates prepared by a different route. Peptide conjugates of adriamycin (Gly-Gly- 
Leu-ADR and Gly-Gly-Gly-Leu-ADR) were synthesized using the trityl N-protecting 
group and were coupled to PGA in 4.5 mol.% load according to the method described 
earlier (I1 f. Howeuer, these conjugates were almost totally devoid of cell ~owth-inhibiting 
activity in L1210 and B16 in vitro tests. The data suggest that either the uptake of the 
polymeric prodrugs into the cell by pinocytosis is highly dependent on spacer load or 
molecular weight, or that lysosomal digestion is too slow for efficient release of ADR. 
Possibly, enzymatic de~adation of PGA which is known to occur only between pH 4 and 6 
is rate-limiting for release of the drug. Current studies include the enzymatic degradation of 
PGA-peptide spacer-drug systems using ~-nitroaniline as a model drug and papain as the 
enzyme. By variation of the length and load of spacer it can be estimated under which 
conditions the release of drug (using UV spectrometry) is faster than de~adation of the 
polymer (as determined by viscometry). In addition, the uptake of PGA and derivatives with 
a fluorescent label into tumor cells is studied using laser flow cytometry and laser micro- 
scopy. 
INTRODUCTION 
High molecular weight prodrugs of cyto- 
static agents have been developed to decrease 
the toxic side effects of the drugs and to 
achieve a more selective administration of the 
agents to tumor cells [l- -6 and references 
cited therein]. Ideally the conjugates of the 
drug and the polymeric carrier should be 
*Paper presented at the Second International Sympo- 
sium on Recent Advances in Drug Delivery Systems, 
February 27, 28 and March 1, 1985. Salt Lake City, 
UT, U.S.A. 
stable in the circulation and should degrade 
only after uptake by tumor cells. Degradation 
of the conjugate takes place in the lysosomal 
compartments by exposure to a number of 
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digestive enzymes at an acidic pH (4-5) 
[ 7-91 releasing the parent drug in situ. 
In previous papers [ 10,111 we have de- 
scribed a series of high molecular weight pro- 
drugs of adriamycin using polyps-L-glutamic 
acid), PGA, as a carrier and peptides of differ- 
ent length and composition as spacer units. 
Depending on the composition of the con- 
jugates different cytotoxic activities against 
L1210 leukemia cells were observed. How- 
ever, the cytotoxic activities were always 
lower as compared to that of the free drug. In 
principle, this may be due to a slow uptake or 
no uptake at all of the conjugate by the 
tumor cell or a to a very low rate of degrada- 
tion of the conjugate after internalization by 
the tumor cell. 
In this paper we will report on the 
synthesis of some new conjugates of adria- 
mycin and PGA, the interaction of conjugates 
with mouse leukemia L1210 cells studied 
with laser flow cytometry and the enzymatic 
degradation of the carrier and the conjugates 
using papain as a model enzyme. 
SYNTHESIS AND CYTOCIDAL ACTIVITY OF 
MACROMOLECULAR PRODRUGS OF 
ADRIAMYCIN 
The synthesis of poly(cr-l-glutamic acid), 
PGA, was described previously [12,13]. The 
conjugates PGA2 , PGA, and PGA8 had molec- 
DMF 
Et-Da - AORIAMYCIN 
uiar weights (M,) of 13 X 104, 7.1 X lo4 and 
6.3 X 104, respectively, as determined by 
viscometry using the relation [q] = 3.13 X 
lo-3 ,ii;iw)0.96S 
[ 141. Direct coupling of adria- 
mycin (ADR) onto PGA was carried out by 
usingN-ethoxycarbonyl-2-ethoxy-1,2-dihydro- 
quinofine, EEDQ, as a coupling agent (Fig. 1). 
This procedure allows the selective coupling 
of the amino group in the daunosamine 
moiety of adriamycin without the concomi- 
tant formation of esters. The conjugates desig- 
nated as P,--A (X refers to the batch of PGA) 
were obtained in yields up to 97% and with 
16-22 weight percent of adriamycin. It was 
noticed that adriamycin readily gives 77 com- 
plexes with the P-A conjugates and com- 
plexed adriamycin has to be removed by ion- 
exchange chromato~aphy [ 1 l] before 
biological testing of the conjugates. 
The attachment of adriamycin onto PGA 
through spacer groups was carried out in two 
ways, which are depicted schematically in 
Fig. 2. In an earlier approach [ll] we first 
introduced different peptide spacers onto the 
PGA via preactivation with saccharin and 
~,~‘-c~bonyldiimid~ole and subsequent 
reaction of the saccharin imides with 
N, N,N’,N’-tetramethylguanidine salts of the 
oligopeptides. The degrees of substitution 
usually obtained were in between 90-100% 
of available carboxylic acid groups of the 
polymers. Typical spacers used are Gly-Gly- 
Leu and Gly-Gly-Gly-Leu. After grafting of 
Fig. 1. Chemical coupling of adriamycin with PGA. 
rmcec 85-100 45 
AOR L- to 65 
Fig. 2. General structures of two types of macro- 
molecular prodrugs of adriamycin using PGA as the 
carrier. 
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PGA with the spacer, adriamycin was again 
coupled with EEDQ. The resulting conjugates 
are designated for instance as P,-GGGL-A, 
where P = PGA, G = Gly , L = Leu and A = 
adriamycin, and the index indicates the batch 
number of PGA. The degree of substitution of 
adriamycin onto the grafted carriers varies 
between 3.6 and 10 mol.% of available 
carboxylic acid groups. 
An alternative way to attach adriamycin 
onto PGA through spacer functions is to first 
prepare adriamycin-spacer entities which are 
subsequently coupled onto PGA. The syn- 
thetic approach is depicted in Fig. 3. The 
appropriate N-trityl protected spacers were 
synthesized in overall yields of 75-97%. 
After activation through the N-hydroxy- 
succinimide ester, adriamycin was coupled 
giving the protected adriamycin spacer com- 
pounds in 80--82%. Removal of the N-trityl 
group by 75% acetic acid gave the unprotected 
adriamycin spacer, which was isolated as the 
HCl salt in 75-79s. These residues were then 
coupled onto PGA using the EEDQ method 
described previously. After purification and 
lyophilization polymers with 4.5 mol. % 
adriamycin residues were obtained. These 
conjugates are further designated as P,- 
[spacer-A]. 
TABLE 1 
All conjugates described above were tested 
for their anti-tumor activity using the L1210 
clonogenic and the B16 mouse melanoma 
liquid assays. The results are given in Table 1. 
Trt-Gly-ON% + H-IGlyIn-Leu-OH (n=l. 21 
175-79 %I 
I 
NEtM lDMFl 
Trt -(Gly),-Leu-OH (nz2.31 
1 DCC I. HONSu ICH2Cll 1 
180-82 %I 
I 
2 ADR HCI, NEtM iDt.IF) 
3. chromatography on s~llcagel 
Trt -iGly),-Leu-AOR in=2.3) 
1 75 % HOAc 
175-79 %I I 2. 0 01 N HCI I1 equw ) 
HCI.(Gly),-Leu-ADR in=2.3) 
Trt : Trltyl N-protecting group 
ADR - Adrlomycln 
NEtM: N-ethylmorphol~ne 
DCCI I N,N’-d,cyclohexyICorbOd~lmlde 
HONSu: N-hydroxysucc~n~m~de 
Fig. 3. Synthesis of peptide-adriamycin conjugates. 
ID,, values of adriamycin and adriamycin conjugatesobtained with the L1210 clonogenic 
and the B16 liquid assays 
Compound Codea Load b ID,, L1210 assay ID,, B16 assay 
(mol.%) (ng A/ml) (ng A/ml) 
Free drug A _ 21124 4-5 
Conjugate P,--A 5 1100/4100 - 
Conjugate P,-GGL-A 9614.3 200 70 
(spacer) P,-G-GGL-A 95167110 1100/3300 270 
P,-GGL-A 8918 3000 220 
P,-GGGL-A 8418 560 200 
P,-[ GGL-A] 4.414.4 > 65000 % 650 
P,--[GGGL-A] 4.514.5 > 65000 % 650 
=Indices indicate batch numbers. 
bSubsequent load percentages refer to subsequent substitution with spacer entities and 
adriamycin; A = adriamycin, P = poly(a-L-glutamic acid), G = Gly and L = Leu. 
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From Table 1 it can be observed that the 
conjugate P,-A has a very low activity as 
compared to the free drug. When the P3 and 
P, conjugates are compared, conjugates with 
the GGL spacer provide higher activities as 
compared to those with the G-GGL spacer. 
The latter spacer, however, was prepared in a 
two step procedure with incomplete substitu- 
tion with G and GGL. This still leaves the 
possibility that considerable amounts of adria- 
mycin are coupled onto a G spacer as com- 
pared to the G-GGL spacer. In the P7 series 
conjugates with the GGL spacer give a very 
low activity. However, the adriamycin load is 
twice that of the P3 conjugate, which possibly 
may influence the cytocidal activity. 
Increasing the spacer length of the P, con- 
jugate with one glycine residue, using a direct 
coupling of GGGL onto PGA, gives higher 
activities as compared to the P,-GGL conju- 
gate. Surprisingly the Pa conjugates with both 
a GGL and GGGL spacer show almost no 
activity, although only 4.4-4.5 mol. % of 
adriamycin spacer entities were attached. 
In order to obtain further information, we 
have initiated studies on the interaction of 
conjugates with L1210 cells using laser flow 
cytometry [15]. We have also studied the 
enzymatic degradation of some of the con- 
jugates using papain as a model enzyme. 
INTERACTION OF CONJUGATES WITH MOUSE 
LEUKEMIA LIZ10 CELLS 
The conjugates of PGA and adriamycin are 
designed in such a way that after uptake by 
the cells, degradation by lysosomal enzymes 
may take place and adriamycin or low-molec- 
ular weight adriamycin-peptide units may be 
released. After additional conversion of the 
peptides, free adriamycin enters the nucleus 
and intercalates with DNA which causes an 
inhibition of RNA- and DNA-mediated 
protein synthesis. 
Two mechanisms can be distinguished by 
which the conjugates are taken up by the 
cells. These are adsorptive and passive (fluid- 
phase) pinocytosis as reviewed by Pratten et 
al. [16]. Duncan and Lloyd [8] described the 
pinocytosis of soluble synthetic polymers as 
drug carriers, whereas Kooistra [17] and 
Munniksma et al. [18] studied the pino- 
cytosis of proteins. Parameters affecting the 
pinocytosis of synthetic polymers include the 
type of cell [ 161, the structure of the 
polymer including the molecular weight 
distribution [8], the composition of the 
medium [ 191 and the temperature [20,21]. 
When the polymer has affinity for the cell 
surface, adsorptive pinocytosis takes place 
and the rate of capture of the polymers by 
the cells is enhanced [8,22]. Complexes of 
anthracyclines and DNA [23] and covalently 
bound conjugates of daunomycin and 
albumin were studied in uiuo [5] and in vitro 
[9] with mouse leukemia L1210 cells. The 
interaction of the former complexes with 
sarcoma, lymphoma and human leukemia 
cells in vitro was also studied with fluores- 
cence microscopy and compared with that of 
the free drug [4]. It was shown that the 
macromolecular anthracycline complexes 
were internalized by the cells and then 
accumulated in lysosomes. The interaction of 
protein-bound methotrexate with L1210 cells 
was studied by Chu and Whitely [6]. 
We have used laser flow cytometry using 
the adriamycin fluorescence [15] to study 
the interaction of L1210 cells with the 
polymeric conjugate P,-A, which presumably 
has the same very weak cytotoxic action as 
P?-A (cf. Table 1) and appears to be quite 
stable on treatment with papain (see below). 
L1210 cells (0.5 ml of 1 X lo6 cells/ml in 
culture medium) were exposed to the con- 
jugate P,--A which has a load of 6.3 mol.% 
of adriamycin-equivalents (0.125 ml of 1.0 
mg/ml in PBS) at 37°C for 3 h. The cells were 
washed twice with phosphate buffered saline 
(PBS) centrifugated and resuspended in PBS 
prior to flow cytometry. The samples were 
measured in a home-built flow cytometer 
using a 3 watt argon ion laser tuned to 488 
nm. The forward light scattering, orthogonal 
light scattering and fluorescence emission at 
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Fig. 4. Flow cytometric analysis of untreated mouse 
leukemia L1210 cells and of cells which were exposed 
to the polymeric conjugate P,-A at 37°C for 3 h. 
Conditions: see text. 
90” were analyzed with a home-made multi- 
channel analyzer connected to a LSI 11/23 
minicomputer. For each experiment data 
were collected for 10,000 to 12,000 cells. The 
forward light scattering gives information 
about the cell size and the fluorescence is 
related to the amount of adriamycine asso- 
ciated with the cells. 
Figure 4 shows the relative number of cells 
versus forward light scattering and the relative 
number of cells versus fluorescence (histo- 
gram) as well as two-dimensional dot plots of 
forward light scattering versus fluorescence 
(scatter plot) for cells exposed and cells un- 
exposed to the conjugate P,-A. The signifi- 
cant fluorescence observed with the treated 
cells indicates that the polymeric conjugate 
either binds to or is taken up by the cells. The 
fluorescence intensity at maximum frequency 
(Fig. 4E, arrow) of cells exposed to P,-A 
in culture medium was determined at various 
incubation times at 21°C and 37°C (Fig. 5A). 
Very similar results at both temperatures were 
obtained. The fluorescence increases rapidly 
(within 10 min) to a plateau value. Cells were 
also incubated for various periods in PBS at 
I 
50 00 Ed _.I~ 
I”l ,“l”, 
Fig. 5. Interaction of L1210 cells with conjugate 
P,-A as determined with flow cytometry (Fig. 4). 
Dependence of the cell-associated adriamycin fluor- 
escence on incubation time in culture medium at two 
temperatures (A) and in PBS at 37°C with different 
concentrations of P,-A (B) Dependence of cell- 
associated fluorescence after 60 min on the concen- 
tration of P,-A in PBS (B insert). 
37°C with different concentrations of P,-A. 
After incubation the cells were also washed 
twice with PBS. Within 10 min plateau values 
were obtained for each concentration of 
P7-A. Higher plateau values were observed 
when the conjugate concentration in the solu- 
tion was increased (Fig. 5B). These data 
strongly suggest that the observed fluores- 
cence is mainly due to adsorption of P,-A 
onto L1210 cells as will be discussed below. 
Pinocytosis is a process requiring metabolic 
energy and is strongly dependent on tempera- 
ture [20,21]. In our experiments the cell 
fluorescence was independent on the tempera- 
ture. Furthermore, the rate of uptake of non- 
degradable polymers by pinocytosis is general- 
ly constant while we have observed a rapid 
initial increase in the amount of cell bound 
conjugate, which then remains constant for 
at least 3 h. Pinocytosis of N-(2-hydroxy- 
propyl)methacrylamide copolymers by rat 
visceral yolk sacs occurs with a constant rate 
for a period of at least six hours [25]. There- 
fore, we conclude that the measured fluores- 
cence of the cells is mainly caused by 
adsorbed prodrug. 
Due to the apparent adsorption of P,-A 
onto the cells, a possible pinocytosis in our 
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case may be obscured. The binding of P,-A 
onto the cells is quite strong, because a sub- 
stantial amount of adsorbed P,-A was not 
removed after two washing steps with PBS. 
Tritton and Yee [26] reported that adria- 
mycin coupled to an insoluble agarose sup- 
port does not enter the cell and is still actively 
cytotoxic for L1210 cells. This was explained 
by a membrane-mediated cytotoxicity. It has 
been reported by Murphree et al. [27] that 
adriamycin induced changes in the surface 
membranes of sarcoma 180 ascites cells. It 
cannot be excluded that the adsorption of 
P,--A onto L1210 cells is mediated by the 
adriamycin moiety. Contrary to the results of 
Tritton et al. [26] the P-A conjugates are 
practically non-cytotoxic, suggesting that 
adriamycin bound to PGA interacts in a 
different way with the cell membrane than 
the insoluble agarose-bound adriamycin 
residue. 
DEGRADATION OF PGA-DERIVED 
ADRIAMYCIN PRODRUGS WITH PAPAIN 
A prerequisite for an efficient lysosomo- 
tropic endocellular release system is that after 
internalization the system is degraded at a 
sufficient rate by the lysosomal enzymes. The 
enzymatic cleavage of drugs from macro- 
molecular carriers has been studied by Trouet 
et al. [ 5,9] using daunomycin bound to 
derivatized proteins and by Kopecek and co- 
workers [4,25] focusing on the release of 
p-nitroaniline as a model compound from 
poly(acrylamide)-type matrices. These studies 
revealed that the length and sequence of the 
peptide spacers used is crucial for the rate of 
drug release. Generally, the spacer should con- 
sist of at least three amino acids, while the 
sequence may be optimized for lysosomal 
(cathepsin mediated) degradation [ 41. 
To study the susceptibility of our conju- 
gates for enzymatic attack, we have 
performed degradation studies with papain 
[28] as a model enzyme. Solution of conju- 
gates in citrate buffer (pH 5.0) were incu- 
0 2M NaCI. 0.05 M Na-citratelcitricacid, 
ptl 5.0. r.t. 
P7-GGGL-A 
-/ 
X 
20 
TIME(h) 
Fig. 6. Time-dependent release of extractable fluores- 
cent products (h,,, = 480 nm, h,, = 560 nm) after 
enzymatic hydrolysis of various PGA-bound adria- 
mycin prodrugs with papain in buffer, pH 5.0 (0.2 M 
NaCl, 0.05 M Na citrate/citric acid, 1 mM EDTA and 
5 mM cysteine). Concentrations: spacer-bound 
conjugates, 2.0 x 10.’ M of ADR equiv., 7 X lo-' M 
of papain; PT-A, 2.1 x 10m4 M of ADR equiv., 3.2 
x lo-' M of papain. 
bated with papain. At appropriate times 
samples were taken, which were mixed with 
borate buffer (pH 10) and extracted with 
chloroform/methanol (4: 1, v/v). The com- 
bined fluorescence intensity of adriamycin 
and/or neutral peptide derivatives of adria- 
mycin in the organic layer was followed 
0 exe = 480 nm and h,, = 560 nm) for differ- 
ent conjugates as a function of time (Fig. 6). 
The data presented in Fig. 6 show that the 
initial release of fluorescent compounds from 
P,-GGGL-A and P,-GGL-A, which are 
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highly substituted by spacers, is significantly 
higher than the release from P,-[GGGL-A] 
with only one spacer residue per adriamycin 
molecule. These data are consistent with 
those on cytotoxic activities presented in 
Table 1. The release of fluorescent com- 
pounds from P,- GGL-A levels off after a 
very short period, which cannot be inter- 
preted at the present time. The conjugate 
with r-glutamyl-bound adriamycin (P,-A) 
does not release fluorescent extractable 
products to a significant extent, which is 
consistent with the specificity of papain for 
cleavage of a-amide bonds. 
TLC analysis of release products from con- 
jugates with a tetrapeptide spacer reveals that 
adriamycin and at least one other compound 
(possibly Gly-Leu-adriamycin) were present 
in the organic phase. The tri-spacer conjugate 
mainly released adriamycin. All data were 
obtained from degradation experiments 
carried out at a pH value of 5.0, which is the 
optimal pH for papain-mediated degradation 
of PGA [29]. The optimum pH for degrada- 
tion is related to the helix-coil transition of 
PGA which has a pH mid value of 5.0. 
We have determined the pH dependence of 
the adriamycin fluorescence intensity in the 
P,-A conjugate (Fig. 7). A pH mid value of 
about 5.5 was found, which indicates that the 
covalently bound adriamycin moiety only 
slightly modifies the conformation of the 
main chain. Therefore, it cannot be excluded 
that with the P,-A conjugate also cleavage 
of the main chain takes place. The pH depen- 
dent fluorescence of adriamycin showed a 
different course as compared to that of the 
conjugate. 
We have applied viscometry using a micro 
Ubbelohde type instrument for the study of 
the PGA-backbone degradation by papain. 
PGA as well as the conjugate P,-A were 
incubated with papain in a buffer solution at 
pH 5.3 and the relative viscosity (qt.) was 
determined at various times (Fig. 8). The 
parent polymer, PGA8, which has a molecular 
weight comparable to that of PGAT, was 
degraded as expected [29]. The viscosity of 
the adriamycin derivative P,-A is much lower 
PBS/CITRIC ACID 
Fig. 7. Dependence of the fluorescence emission 
(A exe = 488 nm, A,, = 564 nm) of adriamycin and 
P,-A on pH. 
than that of the parent polymer and remains 
constant after a small initial decrease upon 
treatment with the enzyme. The lower initial 
viscosity of the conjugate may be explained 
by some bond cleavage during the coupling 
procedure or by an effect of the adriamycin 
moiety on the polymer conformation. The 
latter possibility is unlikely because a con- 
formational transition of the P,-A conjugate 
occurs at almost the same pH as with PGA. 
The small initial decrease in viscosity ob- 
served with P,-A after papain treatment 
can be explained by rapid cleavage of some of 
the amide bonds in the main chain. Possibly 
oligomers of glutamic acid with adriamycin 
residues are not susceptible to further 
enzymatic degradation. 
212 
pH 5 3, 25.0 Y 
. 
Papaln (3 x10-6 MI 
Fig. 8. Enzymatic degradation of PGA, and P---A 
with papain in buffer, pH 5.3 (0.2 M NaCI, 0.05 M 
Na citrate/citric acid, 1 mM EDTA and 5 mM 
cysteine) at 25°C. Dependence of relative viscosity 
(Q) on incubation time. Polymer concentrations: 
PGA,, 2.2 mg/ml (free acid); P,-A, 2.1 mg/ml 
(Na salt). 
CONCLUSIONS 
Adriamycin and adriamycin-peptide 
residues were released from PGA conjugates 
by papain enzyme when tri- or tetrapeptide 
were used as spacers. This result is consistent 
with the findings of Trouet et al. [5,9] and 
Kopecek et al. [ 4,251. 
PGA conjugates of adriamycin with one 
spacer unit per adriamycin molecule show a 
substantial lower cytotoxicity as compared 
to conjugates which were first almost com- 
pletely substituted with spacer units and then 
reacted with adriamycin. 
The rate of enzymatic degradation of these 
conjugates is in accordance with their cyto- 
toxicity. 
When conjugates of adriamycin and PGA 
without a spacer were contacted with L1210 
cells a rapid concentration dependent adsorp- 
tion was observed. 
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